At the AAM Biosimilar Council Conference 2017, Hillel Cohen, executive director of scientific affairs at Sandoz, disambiguated key terms in biosimilars.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.